Invention Grant
- Patent Title: Oligomeric compounds for the modulation of survivin expression
- Patent Title (中): 用于调节存活蛋白表达的低聚化合物
-
Application No.: US12765673Application Date: 2010-04-22
-
Publication No.: US08026355B2Publication Date: 2011-09-27
- Inventor: Jens Bo Rode Hansen , Charlotte Albaek Thrue , Majken Westergaard , Kamille Dumong Petersen , Margit Wissenbach
- Applicant: Jens Bo Rode Hansen , Charlotte Albaek Thrue , Majken Westergaard , Kamille Dumong Petersen , Margit Wissenbach
- Applicant Address: DK Horsholm US NJ Bridgewater
- Assignee: Santaris Pharma A/S,Enzon Pharmaceuticals, Inc.
- Current Assignee: Santaris Pharma A/S,Enzon Pharmaceuticals, Inc.
- Current Assignee Address: DK Horsholm US NJ Bridgewater
- Agency: Dechert LLP
- Main IPC: C07H21/04
- IPC: C07H21/04

Abstract:
Oligonucleotides directed against the survivin gene are provided for modulating the expression of survivin. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the survivin. Methods of using these compounds for modulation of survivin expression and for the treatment of diseases associated with either overexpression of survivin, expression of mutated survivin or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleosides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.
Public/Granted literature
- US20100292311A1 OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION Public/Granted day:2010-11-18
Information query